Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁴ Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
⁵ Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁶ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address: nleboeuf@bwh.harvard.edu.

Caroline A Nelson et al. J Am Acad Dermatol. 2022 Dec.

. 2022 Dec;87(6):1400-1402.

doi: 10.1016/j.jaad.2019.12.068. Epub 2020 Jan 10.

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁴ Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
⁵ Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁶ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address: nleboeuf@bwh.harvard.edu.

No abstract available

Comment in

Comment on "Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes".
Apalla Z, Lazaridou E, Lallas A. Apalla Z, et al. J Am Acad Dermatol. 2022 Dec;87(6):e249. doi: 10.1016/j.jaad.2020.04.174. Epub 2020 May 13. J Am Acad Dermatol. 2022. PMID: 32413449 No abstract available.